Patent ID: 9060991
Filing Date: 2015-06-23
Classification: A61K,A61P

Abstract:
1. A method of improving memory in a subject comprising administering to the subject a pharmaceutically acceptable amount of a peptide analogue of glucagon-like peptide-1 (7-36) selected from the group consisting of a peptide analogue 10 to 31 amino acids in length and comprising at least the first 10 amino acids from the N-terminal end of the sequence identified in SEQ ID NO: 1; a peptide analogue 10 to 31 amino acids in length comprising at least the first 10 amino acids from the N-terminal end of the sequence identified in SEQ ID NO: 1 and further comprising N-terminal glycation; a peptide consisting of the sequence identified in SEQ ID NO: 1; a peptide consisting of SEQ ID NO:1 with N-terminal glycation; a peptide analogue 10 to 31 amino acids in length and comprising at least the first 10 amino acids from the N-terminal end of the sequence identified in SEQ ID NO:2 wherein X 1 is selected from L-His and D-His, X 2 is selected from L-Val and D-Val, and X 3 is selected from L-Glu and D-Glu; a peptide analogue consisting of the sequence identified in SEQ ID NO: 4; a peptide analogue 10 to 31 amino acids in length and comprising at least the first 10 amino acids from the N-terminal end of the sequence identified in SEQ ID NO:2 wherein X 1 is selected from L-Asp and D-Asp, X 2 is selected from L-Ala and D-Ala, and X 3 is selected from L-Glu and D-Glu; a peptide analogue consisting of the sequence identified in SEQ ID NO: 3; a peptide analogue 10 to 31 amino acids in length and comprising at least the first 10 amino acids from the N-terminal end of the sequence identified in SEQ ID NO:2 wherein X 1 is selected from L-His and D-His, X 2 is selected from L-Ala and D-Ala, and X 3 is selected from L-Pro and D-Pro; a peptide analogue consisting of the sequence identified in SEQ ID NO: 5; a peptide analogue 10 to 31 amino acids in length and comprising at least the first 10 amino acids from the N-terminal end of the sequence identified in SEQ ID NO:2, wherein X 2 is Ala or Val and wherein the peptide analogue further comprises addition of L-Glu, D-Glu, or addition of a C-16 palmitoyl fatty acid at Lys(20), or an amino acid substitution by L-Arg or D-Arg at Lys(28) of SEQ ID NO:2; and a peptide analogue Arg(34)Lys(26)-(N-epsilon-(gamma-Glu) (N-alpha-hexadecanoyl))GLP-1(7-37).